Apellis Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 5 | -$0.48 | -$0.48 | -$0.48 |
| Q2 2024 | 6 | -$0.31 | -$0.31 | -$0.31 |
| Q3 2024 | 15 | -$0.40 | -$0.20 | -$0.29 |
| Q4 2024 | 6 | -$0.19 | -$0.19 | -$0.19 |
| Q1 2025 | 14 | -$0.07 | -$0.07 | -$0.07 |
| Q2 2025 | 14 | -$0.06 | -$0.06 | -$0.06 |
| Q3 2025 | 14 | -$0.08 | -$0.08 | -$0.08 |
| Q4 2025 | 14 | $0.11 | $0.11 | $0.11 |
| Q1 2026 | 8 | $0.34 | $0.34 | $0.34 |
| Q2 2026 | 8 | $0.54 | $0.54 | $0.54 |
| Q3 2026 | 8 | $0.68 | $0.68 | $0.68 |
| Q4 2026 | 8 | $0.84 | $0.84 | $0.84 |
Apellis Pharmaceuticals, Inc. Earnings Date And Information
Apellis Pharmaceuticals, Inc. last posted its earnings results on Thursday, August 1st, 2024. The company reported $-0.28 earnings per share for the quarter, topping analysts' consensus estimates of $-0.33 by $0.05. The company had revenue of 199.69 M for the quarter and had revenue of 396.59 M for the year. Apellis Pharmaceuticals, Inc. has generated $-4 earnings per share over the last year ($-4.45 diluted earnings per share) and currently has a price-to-earnings ratio of -10.63. Apellis Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based on prior year's report dates.
Apellis Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/01/2024 | Q2 2024 | -$0.33 | -$0.30 | 0.03 | $190.89 M | $199.69 M |
| 05/07/2024 | Q1 2024 | -$0.54 | -$0.54 | 0 | $172.33 M | |
| 02/29/2024 | Q4 2023 | -$0.73 | $146.38 M | |||
| 11/01/2023 | Q3 2023 | -$0.84 | -$1.17 | -0.33 | $99.05 M | $99.18 M |
| 07/31/2023 | Q2 2023 | -$1.35 | -$1.02 | 0.33 | $70.24 M | $94.97 M |
| 05/04/2023 | Q1 2023 | -$1.42 | -$1.56 | -0.14 | $44.85 M | |
| 02/21/2023 | Q4 2022 | -$1.65 | -$1.50 | 0.15 | $22.66 M | |
| 11/07/2022 | Q3 2022 | -$1.48 | -$1.75 | -0.27 | $21.59 M | $22.06 M |
| 08/08/2022 | Q2 2022 | -$1.43 | -$1.46 | -0.03 | $16.95 M | $16.32 M |
| 05/04/2022 | Q1 2022 | -$1.36 | -$1.42 | -0.06 | $14.38 M | |
| 02/28/2022 | Q4 2021 | -$1.32 | -$1.73 | -0.41 | $60.29 M | |
| 11/08/2021 | Q3 2021 | -$1.73 | -$2.28 | -0.55 | $7.23 M | $5.65 M |
| 08/09/2021 | Q2 2021 | -$1.70 | -$2.72 | -1.02 | $500,100 | $623,000 |
| 04/28/2021 | Q1 2021 | -$1.69 | -$2.32 | -0.63 | $0 | |
| 02/25/2021 | Q4 2020 | -$0.75 | $0.99 | 1.74 | $250.00 M | |
| 11/02/2020 | Q3 2020 | -$1.53 | -$1.79 | -0.26 | $646,000 | |
| 07/30/2020 | Q2 2020 | -$1.57 | $0 | |||
| 04/29/2020 | Q1 2020 | -$1.33 | -$2.29 | -0.96 | $0 | |
| 02/27/2020 | Q4 2019 | -$1.15 | -$1.54 | -0.39 | $-142,150 | |
| 11/05/2019 | Q3 2019 | -$1.04 | -$1.10 | -0.06 | $0 |
Apellis Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Apellis Pharmaceuticals, Inc.'s earnings date?
Apellis Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off last year's report dates.
-
Did Apellis Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Apellis Pharmaceuticals, Inc. (:APLS) reported $-0.28 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.33 by $0.05.
-
How can I listen to Apellis Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Apellis Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Apellis Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Apellis Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Apellis Pharmaceuticals, Inc. generate each year?
Apellis Pharmaceuticals, Inc. (:APLS) has a recorded annual revenue of $396.59 M.
-
How much profit does Apellis Pharmaceuticals, Inc. generate each year?
Apellis Pharmaceuticals, Inc. (:APLS) has a recorded net income of $396.59 M. Apellis Pharmaceuticals, Inc. has generated $-4.45 earnings per share over the last four quarters.
-
What is Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio?
Apellis Pharmaceuticals, Inc. (:APLS) has a price-to-earnings ratio of -10.63 and price/earnings-to-growth ratio is -0.51.
